[HTML][HTML] Dendritic cells in transplantation and immune-based therapies
JW Young, M Merad, DNJ Hart - Biology of Blood and Marrow …, 2007 - Elsevier
Dendritic cells (DCs) are specialized, bone marrow–derived leukocytes critical to the onset
of both innate and adaptive immunity. The divisions of labor among distinct human DC …
of both innate and adaptive immunity. The divisions of labor among distinct human DC …
Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias
AJ Barrett, K Rezvani - Clinical & Experimental Immunology, 2007 - academic.oup.com
The graft-versus-leukaemia (GVL) effect following allogeneic stem cell transplantation is
clear evidence that T lymphocytes can control and eliminate myeloid leukaemias. The …
clear evidence that T lymphocytes can control and eliminate myeloid leukaemias. The …
A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by …
YX Chen, K Man, GS Ling, Y Chen, BS Sun… - The Journal of …, 2007 - journals.aai.org
The dendritic cell (DC)-based tumor immunotherapy has been a new promise of cure for
cancer patients, but animal studies and clinical trials have thus far only shown limited …
cancer patients, but animal studies and clinical trials have thus far only shown limited …
[PDF][PDF] Non-contact measurement of soil moisture content using thermal infrared sensor and weather variables
T Alshikaili - 2007 - harvest.usask.ca
The use of remote sensing technology has made it possible for the non-contact
measurement of soil moisture content (SMC). Many remote sensing techniques can be used …
measurement of soil moisture content (SMC). Many remote sensing techniques can be used …
Evidence that a BCR–ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro
HM Abu-Eisha, NM Butt, RE Clark, SE Christmas - Leukemia research, 2007 - Elsevier
The BCR–ABL fusion protein is characteristic of chronic myeloid leukaemia and may be an
effective tumour-specific antigen. CD8+ T cell responses to BCR–ABL fusion peptides have …
effective tumour-specific antigen. CD8+ T cell responses to BCR–ABL fusion peptides have …
[PDF][PDF] NEW FRONTIERS IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC MYELOGENOUS LEUKEMIA
S Gupta, J Pinilla-Ibarz, P Maslak… - Clinical Malignant …, 2007 - ndl.ethernet.edu.et
The introduction of imatinib mesylate to the therapy of chronic myeloid leukemia (CML)
radically changed the clinical management of patients with this disorder and ushered in the …
radically changed the clinical management of patients with this disorder and ushered in the …
[PDF][PDF] A Crucial Role for Dendritic Cell (DC) IL-10
CLS Lin, F Huang, FP Huang, IOLN Lo, LC Chan… - J Immunol, 2007 - academia.edu
The dendritic cell (DC)-based tumor immunotherapy has been a new promise of cure for
cancer patients, but animal studies and clinical trials have thus far only shown limited …
cancer patients, but animal studies and clinical trials have thus far only shown limited …
[引用][C] NEW FRONTIERS IN THE
ORR CHRONIC - Clinical Malignant Hematology, 2007 - McGraw-Hill Professional